Publikationen (13) Publikationen von SARA IBÁÑEZ GARCÍA

2023

  1. Hacia la excelencia en la atención farmacéutica al paciente quirúrgico

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 47, Núm. 1, pp. 26-30

  2. Medication guide for dose adjustment and management of cardiotoxicity and lipid metabolic adverse events of oral antineoplastic therapy

    Frontiers in Oncology, Vol. 13

2022

  1. PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort

    Biomedicine and Pharmacotherapy, Vol. 146

2021

  1. Clinical evaluation of pulmonary hypertension using patient-reported outcomes: a cross-sectional study

    BMC Pulmonary Medicine, Vol. 21, Núm. 1

  2. Levels of tacrolimus after treatment for chronic hepatitis C with direct antiviral agents in solid organ transplant recipients

    International Journal of Clinical Pharmacy, Vol. 43, Núm. 3, pp. 731-736

2020

  1. Risks and medication errors analysis to evaluate the impact of a chemotherapy compounding workflow management system on cancer patients’ safety

    Health Informatics Journal, Vol. 26, Núm. 3, pp. 1995-2010

2019

  1. Cancellations of elective surgical procedures due to inadequate management of chronic medications

    Journal of Clinical Pharmacy and Therapeutics, Vol. 44, Núm. 4, pp. 561-564

  2. Development and Evaluation of a Clinical Decision Support System to Improve Medication Safety

    Applied Clinical Informatics, Vol. 10, Núm. 3, pp. 513-520

2018

  1. Multidisciplinary strategy to reduce errors with the use of medical gases

    Farmacia Hospitalaria, Vol. 42, Núm. 3, pp. 103-107

2017

  1. Improving pharmacotherapy outcomes in patients with hepatitis C virus infection treated with direct-acting antivirals: The GRUviC project

    International Journal of Clinical Practice, Vol. 71, Núm. 8

2016

  1. Adding value through pharmacy validation: A safety and cost perspective

    Journal of Evaluation in Clinical Practice, Vol. 22, Núm. 2, pp. 253-260

  2. Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice

    Annals of Pharmacotherapy, Vol. 50, Núm. 11, pp. 901-908

  3. Smartphone applications for cancer patients; what we know about them?

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 40, Núm. 1, pp. 25-35